CEO of Covid antibody maker Vir Biotech says their treatment ‘stands up well’ to all variants
The monoclonal antibody Covid is used for treatment Vir BiotechnologyAnd GlaxoSmithKlineGeorge Scangos, Vir CEO and President said that the virus “stands well” against all forms of it.Power Lunch” Wednesday.
Scangos comments were made after Scangos and two other companies disclosed contracts for $1 billion in sotrovimab sales to the U.S. government. Sotrovimab was granted an emergency authorization by the Food and Drug Administration in May for moderate Covid infections.
FDA states that the antibody, which is intravenously administered, was designed to inhibit Covid’s spike proteins from reaching human cells and stopping them from penetrating and attaching to them.
Scangos stated that “it certainly is an effective anti-Covid antibody, as well as against SARS and many other coronaviruses.” So, not only do we now have an antibody which is effective against all variants of Covid but also potentially it can be used to help with future coronavirus pandemics.”
Scangos acknowledged that the delta variant, which is highly transmissible, will “be with us for some time,” and he said sotrovimab may be able protect against future variants. Scangos stated that the future variants could be variations of delta, much like those described in the delta plus subvariantOfficials in the U.K. began to monitor a growing number of cases in this autumn.
Two mutations occur in Delta Plus to the spike protein, which Covid enters the body via. However, the subtype of the spike protein has not evolved enough to warrant being considered its own type.
Scangos reported that Vir and GSK received worldwide orders for 750,000 doses. According to Vir, the $1 billion order will be delivered to the federal government by December 17. The U.S. has the option of purchasing additional doses up to March next year.
Scangos stated that Covid is capable of traveling between animals and humans. “As long as there are animal reservoirs, the virus can be transmitted to animals, mutations, new versions, and then back to humans. We’re not out of luck.”